The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
The association has lined up a string of prominent speakers from the government and private sector. Seasoned veterans and industry bigwigs will grace the two-day event in Mumbai
This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls
Gomez joins Moderna from Dentsply Sirona, where he served as Executive Vice President & Chief Financial Officer since August 2019
Ideal power boosters to strengthen muscles and keep energised for all kinds of physical activities
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Subscribe To Our Newsletter & Stay Updated
